Given that the productive CD8+ T cell-mediated anti-tumour immunity is dependent on the ability to traffic to the TME [5], this study supports the clinical findings, which have demonstrated the augmented expression of MHC Class I and the improvement of CD8+ T cell response and infiltration in tumour tissues of patients following VEGF blockade via Bevacizumab [20,21,43]. The gene discussed is VEGFA; the disease is neoplasm.